ArticleDiscover oncology2026
Construction of a prognostic model based on protein post-translational modification genes for prediction of immune characteristics and therapeutic response in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeBy leveraging protein post-translational modification (PTM) genes, we developed a prognostic model for hepatocellular carcinoma (HCC), providing a novel approach for predicting patient outcomes and their response to immunotherapy. This model introduces a potentially valuable tool for improving clinical decision-making in HCC treatment.
methodsPTM-related genes were sourced from the MsigDB database, and key prognostic genes were identified using weighted gene co-expression network analysis (WGCNA) and univariate Cox regression analysis. Prognostic models were constructed through the evaluation of 101 machine learning algorithm combinations, and the model’s predictive accuracy was tested using an independent validation dataset. Additionally, we investigated differences in biological functions, immune status, mutation burden, immunotherapy responsiveness, and chemotherapy sensitivity across distinct risk groups. Finally, the functions of ANAPC7 and SAMD1 in HCC were verified by in vitro experiments.
resultsWe identified 23 prognostic PTM genes, from which prognostic models were constructed using 9 key genes and 101 machine learning combinations. The external validation demonstrated that the models were highly accurate in predicting patient outcomes. Moreover, substantial differences were observed between high-risk and low-risk groups in terms of biological functions, immune cell infiltration, mutation burden, and sensitivity to both immunotherapy and chemotherapy. In vitro results showed that ANAPC7 and SAMD1 were able to promote the proliferation, invasion and migration of HCC.
conclusionOur prognostic model, based on PTM-related genes, successfully predicts both the prognosis of HCC patients and their responsiveness to immunotherapy. This model has the potential to aid in the clinical management of HCC, guiding personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.